• HyperScribe T7 High Yield RNA Synthesis Kit Workflow

  2026-09-29

  Build high-output IVT workflows for capped, labeled, modified, and research-grade RNA, from template preparation through quality control. The workflow also shows how transcript production can support RNA vaccine research while keeping upstream synthesis separate from downstream LNP formulation and animal efficacy testing.

• BCL-XL inhibitor A-1155463 Workflow

  2026-09-29

  Build a dependency-aware apoptosis workflow with A-1155463, from DMSO handling and cell-line selection to orthogonal validation and in vivo interpretation. The approach connects selective BCL-XL inhibition with resistant solid-tumor models, glioblastoma stem-like cells, and hematological malignancies research while keeping preclinical claims appropriately bounded.

• Saquinavir Permeability Workflows for HIV Research

  2026-09-28

  Saquinavir can serve as both a mechanistic HIV protease inhibitor and a demanding probe for membrane-interaction studies. This workflow combines biomimetic chromatography, mass spectrometry, and functional assays to support antiretroviral drug research while clarifying what permeability data can—and cannot—predict.

• rTMS Restores Cognition via GABAergic Cx3cl1 Signaling

  2026-09-28

  A 2025 study in 5xFAD mice links repetitive transcranial magnetic stimulation (rTMS) to cognitive improvement, increased neuronal Cx3cl1 signaling, and enhanced microglial responses associated with amyloid clearance. Its single-cell and tissue-level analyses offer a mechanistic framework for studying non-invasive intervention in Alzheimer’s disease, while leaving important questions about stimulation parameters and clinical translation open.

• Oligomycin A as a Probe of Immunometabolic Causality

  2026-09-27

  Oligomycin A is a mitochondrial ATP synthase inhibitor that can help researchers test how respiratory capacity shapes cellular responses. This article connects mitochondrial perturbation to immunometabolic research while distinguishing what the evidence supports from what remains to be tested.

• Torin2 Workflows for Cancer Drug Response Assays

  2026-09-26

  Torin2 helps researchers probe mTOR pathway dependence in cancer models, including medullary thyroid carcinoma cells. Pairing growth measurements with direct cell-death readouts makes its effects easier to interpret than relying on a single endpoint.

• CH 223191: Interpreting AhR Antagonism Across Models

  2026-09-25

  CH 223191 is an aryl hydrocarbon receptor antagonist that helps researchers test whether AhR activation is causal or merely associated with a biological response. This article connects dioxin toxicology with microbiota-driven intestinal repair while clarifying what one antagonist experiment can—and cannot—establish.

• Alfuzosin HCl: Translating α1 Blockade into BPH Research

  2026-09-25

  Alfuzosin HCl offers translational researchers a practical way to study how α1-adrenergic antagonism changes lower urinary tract smooth muscle tone. This article connects receptor-level rationale with functional endpoints, formulation considerations, and a validated spectrophotometric approach—while distinguishing symptom-oriented pharmacology from claims about disease modification.

• Mubritinib (TAK 165): Building Causal Metabolic Assays

  2026-09-24

  Mubritinib (TAK 165) is best understood in many cancer models through mitochondrial complex I, not HER2 alone. This article shows how to design experiments that connect target engagement, metabolic change, and cell fate—and how a fibrosis study offers a useful, carefully bounded model for that reasoning.

• BIRB 796 (Doramapimod) for Cell Assays

  2026-09-24

  A scenario-based guide to using BIRB 796 (Doramapimod), SKU A5639, in cell viability, proliferation, apoptosis, and inflammation research. It explains assay controls, compound handling, interpretation limits, and how to assess supplier options using the product’s reported properties and cited evidence.

• Staurosporine for High-Throughput Cell-Killing Assays

  2026-09-23

  Use Staurosporine as a benchmark apoptosis inducer while measuring when—and in what fraction of a cancer-cell population—death occurs. Pair its broad kinase activity with longitudinal microscopy to distinguish population-level killing from cell-to-cell response variability, without mistaking a positive control for a selective pathway probe.

• 2X Taq PCR Master Mix for CRC Assays

  2026-09-23

  Learn how 2X Taq PCR Master Mix supports better-designed colorectal cancer assays, from genotyping to NEIL1 and COL17A1 transcript analysis. This article connects endpoint PCR chemistry with the experimental logic of a pivotal CRC study.

• Streptavidin-HyperFluor 647 in Translational Proteomics

  2026-09-22

  A thought-leadership guide to choosing biotin-dependent fluorescence detection versus biotin-free BmTyr proximity labeling, with practical workflow guidance for microscopy, flow cytometry, FRET, and primary-cell proteomics.

• BIIE 0246: Receptor Logic in Cardiac-Neural Models

  2026-09-22

  BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist for testing receptor-specific signaling in neural, metabolic, and cardiac models. This article translates adipose-neural axis findings into a rigorous assay strategy while defining what Y2R inhibition can—and cannot—demonstrate in arrhythmia research.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-09-21

  This 2021 study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, stemness, migration, and xenograft tumorigenesis. Its mechanistic contribution is the linkage of the c-MYC–G9a–FTH1 axis with HDAC1-associated chromatin regulation, providing a rationale for combining epigenetic and oncogenic-signaling inhibitors.

3644 records 1/243 page Next 12345 下5页 Last page